Dako/Genentech to submit HercepTest and HER2 FISH pharmDx as companion for T-DM1
Dako has signed an agreement with Genentech, member of the Roche Group, to collaborate on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for a Genentech investigational drug candidate, trastuzumab emtansine (T-DM1), in patients with advanced HER2-positive breast cancer. Under the terms of the agreement, Dako and Genentech will work together on the regulatory FDA submissions of HercepTest and HER2 FISH pharmDx to identify cancer patients who may be eligible for treatment with trastuzumab emtansine.
The collaboration is in line with Dako's ongoing strategy to combine its strengths with pharmaceutical companies to grow the offering of its companion diagnostic assays. The agreement comes on the heels of another collaboration between Dako and Genentech on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for another Genentech investigational drug candidate, pertuzumab.